FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Source: Pixabay.com

FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment

According to a press release from Eiger Biopharmaceuticals, the American Food and Drug Administration (FDA) recently granted the Company's experimental hepatitis delta virus drug (hepatitis D), peginterferon lambda, breakthrough therapy…

Continue Reading FDA Grants Breakthrough Therapy Designation to Investigational Hepatitis D Treatment
Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Free-Photos / Pixabay

Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis

According to a story from Healio, a recent study has illustrated that the drug denosumab can improve the bone density of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis…

Continue Reading Study Finds That Denosumab can Boost Bone Density in Primary Biliary Cholangitis and Autoimmune Hepatitis
Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020
Bru-nO / Pixabay

Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020

According to a press release from Synlogic Therapeutics, the Company recently halted development of its investigational hyperammonemia treatment SYNB1020 after an unsuccessful phase 1/2 clinical study. About Hyperammonemia Hyperammonemia is…

Continue Reading Synlogic Halts Development of Investigational Hyperammonemia Treatment SYNB1020
Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A
Pezibear / Pixabay

Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A

According to a story from Charcot-Marie-Tooth News, a recent study has revealed that patients with Charcot-Marie-Tooth disease (CMT) type 1A still display signs of muscle weakness even if they retain…

Continue Reading Study Focuses on Muscle Weakness in Patients with Charcot-Marie-Tooth Disease Type 1A